These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

988 related articles for article (PubMed ID: 32006266)

  • 1. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
    Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
    Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
    Siamashvili M; Davis SN
    Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
    van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
    Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
    Chino Y; Kuwabara M; Hisatome I
    J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D; Indurkar S; Quadri U; Chandekar B
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
    Zhao Y; Xu L; Tian D; Xia P; Zheng H; Wang L; Chen L
    Diabetes Obes Metab; 2018 Feb; 20(2):458-462. PubMed ID: 28846182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors and Mechanisms of Hypertension.
    Briasoulis A; Al Dhaybi O; Bakris GL
    Curr Cardiol Rep; 2018 Jan; 20(1):1. PubMed ID: 29349558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications.
    Scheen AJ
    Diabetes Metab; 2019 Jun; 45(3):213-223. PubMed ID: 30708071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uric acid and the cardio-renal effects of SGLT2 inhibitors.
    Bailey CJ
    Diabetes Obes Metab; 2019 Jun; 21(6):1291-1298. PubMed ID: 30762288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
    Davidson JA
    Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Fu R; Liu H; Ma Y; Qiu X; Dong Z
    Ann Palliat Med; 2021 Jun; 10(6):6467-6481. PubMed ID: 34118855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.